S. C. Smith, T. E. Feldman and J. W. Hirshfeld, “ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) ,” Circulation, Vol. 113, 2006, pp. 166-286.
 S. Silber, P. Albertsson and F. F. Aviles, “Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology,” Eur Heart J, Vol. 26, 2005, pp. 804-847.
 S. D. Wiviott, D. Trenk and A. L. Frelinger, “Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 trial,” Circulation, Vol. 116, 2007, pp. 2923-2932.
 S. Yusuf, F. Zhao and S. R. Mehta, “For the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial Investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” N Engl J Med, Vol. 345, 2001, pp. 494-502.
 S. R. Mehta, S. Yusuf and R. J. Peters, “Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study,” Lancet, Vol. 358, 2001, pp. 527-533.
 S. B. King, S. C. Smith and J. W. Hirshfeld, “Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” Vol. 117, No. 6, 2008, pp. 261-295.
 S. R. Steinhubl, P. B. Berger and J. T. Mann, “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” JAMA, Vol. 288, 2002, pp. 2411-2420.
 P. A. Gurbel, K. P. Bliden and B. L. Hiatt, “Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity,” Circulation, Vol. 107, 2003, pp. 2908-2913.
 D. J. Angiolillo, A. Fernandez-Ortiz and E. Bernardo,“Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting,” Thromb Res, Vol. 115, 2005, pp. 101-108.
 I. Muller, F. Besta and C. Schulz, “Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement,” Thromb Haemost, Vol. 89, 2003, pp. 783-787.
 P. Barragan, J. L. Bouvier and P. O. Roquebert. “Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation,” Catheter Cardiovasc Interv, Vol. 59, 2003, pp. 295-302.
 P. A. Gurbel, K. P. Bliden and W. Samara, “Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study,” J Am Coll Cardiol, Vol. 46, 2005, pp. 1827-1832.
 S. Matetzky, B. Shenkman and V. Guetta. “Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction,” Circulation, Vol. 109, 2004, pp. 3171-3175.
 G. Montalescot, G. Sideris, C. Meuleman and C. Baldit-Sollier, “A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial,” J Am Coll Cardiol, Vol. 48, 2006, pp. 931-938.
 G. Patti, G. Colonna and V. Pasceri, “Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study,” Circulation, Vol. 111, 2005, pp. 2099-2116.
 T. Cuisset, C. Frere and J. Quilici. “Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting,” J Am Coll Cardiol, Vol. 48, 2006, pp. 1339-1345.
 Han Ya-ling, Wang Bin, Li Yi, Xu Kai, “A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation,” Chin Med J, Vol. 122, 2009, pp. 793-797.
 W. Rosamond, K. Flegal and G. Friday, “For the American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics–2007 update: A report from the American heart association statistics committee and stroke statistics subcommittee,” Circulation, Vol. 115, 2007, pp. e69-e171.